PRIVACY POLICY
Effective Date: November 1, 2024
Millicent Pharma Limited (“Millicent Pharma” “we,” “our,” or “us”), provides this privacy policy (“Privacy Policy”) to describe how we collect, use, and share the information of individuals who visit our websites at femlyv.com, femring.com, us.intrarosa.com, or any other website we own or operate or that links to this Privacy Policy (the “Site(s)”). Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as terms defined in our Terms of Service.
Information Collection
When using our Sites or interacting with us, you may voluntarily provide information about yourself, including your name, email address, and any other information you choose to provide. We collect this information when you send an email to us requesting information or interact with us for any other purpose.
We collect information relating to your interactions with us and our Site, including browser type, IP address, pages visited and other activities on the Site, device type, and time and date of visit, and other information we collect through the use of cookies and similar technology.
Information Use
We may use your information for any lawful purpose, including the following:
- To respond to your inquiries;
- To operate and improve our services, including to provide better services, products, and opportunities to our customers and visitors to our Sites;
- To operate, personalize, and improve our Sites, including for analytics purposes;
- To send surveys, promotions, and marketing materials that may be of interest to you;
- To comply with the law and to maintain the security of our Sites; or
- With your consent, or as otherwise disclosed at the time information is collected.
Information Sharing
We may share the information we collect with third parties, including the following:
- With service providers who perform various functions on our behalf;
- As part of a corporate sale, merger, or acquisition, or other transfer of all or part of our assets, including as part of a bankruptcy proceeding;
- Pursuant to a subpoena, court order, governmental inquiry, or other legal process or as otherwise required by law, or to protect our rights or the rights of third parties;
- With your consent or as otherwise disclosed at the time of data collection or sharing.
We may share information that has been de-identified or aggregated without limitation.
Analytics
We may work with third parties that collect data about your use of our Sites and other sites or apps over time for non-advertising purposes. Millicent Pharma uses Google Analytics and other third-party services to improve the performance of our Sites and for analytics and marketing purposes. For more information about how Google Analytics collects and uses data when you use our Site, visit www.google.com/policies/privacy/partners, and to opt out of Google Analytics, visit tools.google.com/dlpage/gaoptout.
Third-Party Links and Tools
Our Sites may provide links to third-party websites or apps. We do not control the privacy practices of those websites or apps, and they are not covered by this Privacy Policy. You should review the privacy policies of other websites or apps that you use to learn about their data practices.
Our Sites may also include integrated social media tools or “plug-ins,” such as social networking tools offered by third parties. If you use these tools to share personal information or you otherwise interact with these features on the Site, those companies may collect information about you and may use and share such information in accordance with your account settings, including by sharing such information with the general public. Your interactions with third-party companies and your use of their features are governed by the privacy policies of the companies that provide those features. We encourage you to carefully read the privacy policies of any accounts you create and use.
Your California Privacy Rights
Under the California Consumer Protection Act (“CCPA”), California residents have certain rights with respect to the personal information collected by businesses. This section contains disclosures required by the CCPA and applies only to “personal information” about California consumers that is subject to the CCPA (“California Personal Information”).
California Personal Information We Collect and Share for a Business Purpose. We collect the following categories of California Personal Information:
| Categories of California Personal Information Collected | Disclosed for business purposes to the following categories of third parties: |
|---|---|
| Personal and online identifiers (such as first and last name, email address, or unique online identifiers) | All categories listed below. |
| Categories of information described in Section 1798.80(e) of the California Civil Code (such as physical characteristics or description, insurance policy number, bank account number, credit card number, debit card number, or any other financial information, medical information, or health insurance information) | All categories listed below. |
| Characteristics of protected classifications under California or federal law (such as race or gender) | All categories listed below. |
| Commercial or transactions information (such as records of personal property or products or services purchased, obtained or considered) | All categories listed below. |
| Internet or other electronic network activity information (such as browsing history, search history, interactions with a website, email, application, or advertisement) | All categories listed below. |
| Biometric information (such as call recordings) | All categories listed below. |
| Geolocation information | All categories listed below. |
Categories of Sources. We and our service providers, acting on our behalf, collect California Personal Information from the following categories of sources:
- From consumers;
- From service providers we have engaged to provide services to us or on our behalf;
- From our affiliates; and
- From non-affiliated third parties, such as pharmacies or copay programs that may collect personal information on our behalf.
Why We Use and Disclose California Personal Information. We and our service providers, acting on our behalf, use and disclose California Personal Information we collect for our commercial and business purposes, as further described in this Privacy Policy. These purposes include, without limitation:
- Our commercial purposes, including marketing and facilitating transactions.
- Our business purposes as identified in the CCPA, which include:
- Auditing related to our interactions with you;
- Detecting and protecting against security incidents, fraud, and illegal activity;
- Debugging;
- Performing services (for us or our service provider) such as account servicing, processing orders and payments, and analytics;
- Internal research for technological improvement;
- Activities to maintain and improve our services; and
- Other one-time uses.
Recipients of California Personal Information. We disclose the categories of California Personal Information designated above for business purposes to the categories of third parties listed below:
- Service providers;
- Affiliates not under the Millicent brand; and
- Data analytics providers.
Your Rights Regarding California Personal Information. California residents have certain rights with respect to the personal information collected by businesses. If you are a California resident, you may exercise the following rights regarding your California Personal Information, subject to certain exceptions and limitations:
- The right to access the categories and specific pieces of personal information we have collected about you;
- The right to request the categories of sources from which we collected your personal information, our purposes for collecting your personal information, the categories of your personal information that we have disclosed for a business purpose, and the categories of third parties with which we have shared personal information; and
- The right to request that we delete the personal information we have collected from you.
To exercise any of the above rights, please contact us:
- By phone at 1-877-514-2221
- By email at privacy@millicentpharma.com
Note that we may need to request additional information from you to verify your identity or understand the scope of your request, although you will not be required to create an account with us to submit a request or have it fulfilled.
Nevada Privacy Rights
Under Nevada law, Nevada residents may submit a request directing us not to make certain disclosures of personal information we maintain about them.
To exercise this right, please contact us:
- By phone at 1-877-514-2221
- By email at privacy@millicentpharma.com
Changes to Our Privacy Policy
If our information practices change, we will post these changes on this page. We encourage you to visit this page periodically to learn of any updates.
Contact Us
If you have questions, comments, or concerns about this Privacy Policy, please contact us at:
privacy@millicentpharma.com.
IMPORTANT SAFETY INFORMATION
WARNING TO WOMEN WHO SMOKE
Do not use FEMLYV if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
What is FEMLYV?
FEMLYV is a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate.
Who should not take FEMLYV?
Your healthcare provider will not give you FEMLYV if you have ever had blood clots or are at a high risk for stroke, heart attack or other heart problems or abnormalities, breast cancer, liver disease, including liver tumors, take any Hepatitis C drug combination containing ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, which may increase levels of the liver enzyme “alanine aminotransferase” (ALT) in the blood, or have any abnormal bleeding from the vagina. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). Do not take birth control pills if you smoke and are over 35 years old, are or think you are pregnant, or have any abnormal bleeding from the vagina.
What else should I know about FEMLYV?
You should stop FEMLYV at least 4 weeks before you have surgery and not restart it until at least 2 weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like FEMLYV, may decrease the amount of milk you make. A small amount of the pill's hormones passes into breast milk.
What are the most serious risks of taking FEMLYV?
Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke.
Call your healthcare provider right away if you have leg pain that does not go away, sudden shortness of breath, sudden blindness (partial or complete), severe pain or pressure in your chest, sudden, severe headache unlike your usual headaches, weakness or numbness in an arm or leg, or trouble speaking, or yellowing of the skin or eyeballs.
What are the common side effects of birth control pills?
The most common side effects of birth control pills are spotting or bleeding between menstrual periods, nausea, breast tenderness, and headache. These side effects are usually mild and usually disappear with time. The most common adverse reactions in clinical trials (greater than or equal to 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.
These are not all the possible side effects of FEMLYV. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see the full Prescribing Information, including BOXED WARNING, and Patient Information.
References: 1. FEMLYV [package insert]. East Hanover, NJ: Millicent Pharma Limited; 2024. 2. FDA Approves Femlyv (norethindrone acetate and ethinyl estradiol) Orally Disintegrating Birth Control Pill. Drugs.com. July 2024. Accessed August 5, 2024. www.drugs.com/newdrugs/fda-approves-femlyv-norethindrone-acetate-ethinyl-estradiol-orally-disintegrating-birth-control-pill-6330.html 3. Data on File. Millicent Pharma Limited. 4. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin® 24 Fe). Contraception. 2007;75(1):16-22. 5. Fumero A, Marrero RJ, Peñate W, Bethencourt JM, Barreiro P. Adherence to oral contraception in young women: beliefs, locus of control, and psychological reactance. Int J Environ Res Public Health. 2021;18(21):11308. 6. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):3-12. 7. Chewable birth control pill unveiled. CBS News. December 8, 2006. Accessed August 5, 2024. www.cbsnews.com/news/chewable-birth-control-pill-unveiled/ 8. Allergan announces launch of TAYTULLA™ (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, the first and only oral contraceptive softgel capsule. PR Newswire. November 10, 2016. Accessed August 5, 2024. https://www.prnewswire.com/news-releases/allergan-announces-launch-of-taytulla-norethindrone-acetate-and-ethinyl-estradiol-capsules-and-ferrous-fumarate-capsules-1-mg20-mcg-the-first-and-only-oral-contraceptive-softgel-capsule-300360428.html
IMPORTANT SAFETY INFORMATION
WARNING TO WOMEN WHO SMOKE
Do not use FEMLYV if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
What is FEMLYV?
FEMLYV is a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate.
Who should not take FEMLYV?
Your healthcare provider will not give you FEMLYV if you have ever had blood clots or are at a high risk for stroke, heart attack or other heart problems or abnormalities, breast cancer, liver disease, including liver tumors, take any Hepatitis C drug combination containing ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, which may increase levels of the liver enzyme “alanine aminotransferase” (ALT) in the blood, or have any abnormal bleeding from the vagina. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). Do not take birth control pills if you smoke and are over 35 years old, are or think you are pregnant, or have any abnormal bleeding from the vagina.
What else should I know about FEMLYV?
You should stop FEMLYV at least 4 weeks before you have surgery and not restart it until at least 2 weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like FEMLYV, may decrease the amount of milk you make. A small amount of the pill's hormones passes into breast milk.
What are the most serious risks of taking FEMLYV?
Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke.
Call your healthcare provider right away if you have leg pain that does not go away, sudden shortness of breath, sudden blindness (partial or complete), severe pain or pressure in your chest, sudden, severe headache unlike your usual headaches, weakness or numbness in an arm or leg, or trouble speaking, or yellowing of the skin or eyeballs.
What are the common side effects of birth control pills?
The most common side effects of birth control pills are spotting or bleeding between menstrual periods, nausea, breast tenderness, and headache. These side effects are usually mild and usually disappear with time. The most common adverse reactions in clinical trials (greater than or equal to 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.
These are not all the possible side effects of FEMLYV. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see the full Prescribing Information, including BOXED WARNING, and Patient Information.
References: 1. FEMLYV [package insert]. East Hanover, NJ: Millicent Pharma Limited; 2024. 2. FDA Approves Femlyv (norethindrone acetate and ethinyl estradiol) Orally Disintegrating Birth Control Pill. Drugs.com. July 2024. Accessed August 5, 2024. www.drugs.com/newdrugs/fda-approves-femlyv-norethindrone-acetate-ethinyl-estradiol-orally-disintegrating-birth-control-pill-6330.html 3. Data on File. Millicent Pharma Limited. 4. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin® 24 Fe). Contraception. 2007;75(1):16-22. 5. Fumero A, Marrero RJ, Peñate W, Bethencourt JM, Barreiro P. Adherence to oral contraception in young women: beliefs, locus of control, and psychological reactance. Int J Environ Res Public Health. 2021;18(21):11308. 6. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):3-12. 7. Chewable birth control pill unveiled. CBS News. December 8, 2006. Accessed August 5, 2024. www.cbsnews.com/news/chewable-birth-control-pill-unveiled/ 8. Allergan announces launch of TAYTULLA™ (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, the first and only oral contraceptive softgel capsule. PR Newswire. November 10, 2016. Accessed August 5, 2024. https://www.prnewswire.com/news-releases/allergan-announces-launch-of-taytulla-norethindrone-acetate-and-ethinyl-estradiol-capsules-and-ferrous-fumarate-capsules-1-mg20-mcg-the-first-and-only-oral-contraceptive-softgel-capsule-300360428.html
IMPORTANT SAFETY INFORMATION
WARNING TO WOMEN WHO SMOKE
Do not use FEMLYV if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
What is FEMLYV?
FEMLYV is a birth control pill. It contains two female hormones, an estrogen called ethinyl estradiol, and a progestin called norethindrone acetate.
Who should not take FEMLYV?
Your healthcare provider will not give you FEMLYV if you have ever had blood clots or are at a high risk for stroke, heart attack or other heart problems or abnormalities, breast cancer, liver disease, including liver tumors, take any Hepatitis C drug combination containing ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, which may increase levels of the liver enzyme “alanine aminotransferase” (ALT) in the blood, or have any abnormal bleeding from the vagina. Tell your healthcare provider if you have ever had any of the above conditions (your healthcare provider may recommend another method of birth control). Do not take birth control pills if you smoke and are over 35 years old, are or think you are pregnant, or have any abnormal bleeding from the vagina.
What else should I know about FEMLYV?
You should stop FEMLYV at least 4 weeks before you have surgery and not restart it until at least 2 weeks after the surgery, due to an increased risk of blood clots. If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like FEMLYV, may decrease the amount of milk you make. A small amount of the pill's hormones passes into breast milk.
What are the most serious risks of taking FEMLYV?
Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more. It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke.
Call your healthcare provider right away if you have leg pain that does not go away, sudden shortness of breath, sudden blindness (partial or complete), severe pain or pressure in your chest, sudden, severe headache unlike your usual headaches, weakness or numbness in an arm or leg, or trouble speaking, or yellowing of the skin or eyeballs.
What are the common side effects of birth control pills?
The most common side effects of birth control pills are spotting or bleeding between menstrual periods, nausea, breast tenderness, and headache. These side effects are usually mild and usually disappear with time. The most common adverse reactions in clinical trials (greater than or equal to 2%) were: headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.
These are not all the possible side effects of FEMLYV. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see the full Prescribing Information, including BOXED WARNING, and Patient Information.
References: 1. FEMLYV [package insert]. East Hanover, NJ: Millicent Pharma Limited; 2024. 2. FDA Approves Femlyv (norethindrone acetate and ethinyl estradiol) Orally Disintegrating Birth Control Pill. Drugs.com. July 2024. Accessed August 5, 2024. www.drugs.com/newdrugs/fda-approves-femlyv-norethindrone-acetate-ethinyl-estradiol-orally-disintegrating-birth-control-pill-6330.html 3. Data on File. Millicent Pharma Limited. 4. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin® 24 Fe). Contraception. 2007;75(1):16-22. 5. Fumero A, Marrero RJ, Peñate W, Bethencourt JM, Barreiro P. Adherence to oral contraception in young women: beliefs, locus of control, and psychological reactance. Int J Environ Res Public Health. 2021;18(21):11308. 6. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):3-12. 7. Chewable birth control pill unveiled. CBS News. December 8, 2006. Accessed August 5, 2024. www.cbsnews.com/news/chewable-birth-control-pill-unveiled/ 8. Allergan announces launch of TAYTULLA™ (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, the first and only oral contraceptive softgel capsule. PR Newswire. November 10, 2016. Accessed August 5, 2024. https://www.prnewswire.com/news-releases/allergan-announces-launch-of-taytulla-norethindrone-acetate-and-ethinyl-estradiol-capsules-and-ferrous-fumarate-capsules-1-mg20-mcg-the-first-and-only-oral-contraceptive-softgel-capsule-300360428.html
FEMLYV™ is a trademark of Millicent Puerto Rico, LLC.
Distributed by Millicent U.S. Inc., East Hanover, NJ 07936.
The Millicent Pharma logo is a registered trademark of Millicent Pharma Limited.
© 2025, Millicent Pharma Limited. All rights reserved. 11/2024
LYV011
FEMLYV™ is a trademark of Millicent Puerto Rico, LLC.
Distributed by Millicent U.S. Inc., East Hanover, NJ 07936.
The Millicent Pharma logo is a registered trademark of Millicent Pharma Limited.
© 2025, Millicent Pharma Limited. All rights reserved. 11/2024
LYV011